Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Effects of Diaphragmatic Kinesio Taping Combined With Pulmonary Rehabilitation on Diaphragm Muscle Thickness in Intensive Care Patients

5 novembre 2026 aggiornato da: Müberra TANRIVERDİ, Bezmialem Vakif University

Investigation of the Effects of Diaphragmatic Kinesio Taping Applied in Addition to Pulmonary Rehabilitation on Diaphragm Muscle Thickness in Intensive Care Unit Patients: A Randomized Controlled Trial

This prospective, three-arm, randomized controlled trial aims to investigate the effects of diaphragmatic Kinesio taping applied in addition to pulmonary rehabilitation on diaphragm muscle thickness and function in intensive care unit (ICU) patients.

A total of 48 patients admitted to the ICU due to respiratory distress will be recruited and randomly assigned to three groups: pulmonary rehabilitation combined with diaphragmatic Kinesio taping, pulmonary rehabilitation alone, and a control group receiving routine patient education. The interventions will be administered over a three-day period.

Diaphragm muscle thickness during inspiration and expiration, diaphragm excursion, and diaphragm thickening fraction will be assessed using ultrasonography at baseline and after the intervention period. Cough-related quality of life, anxiety, and depression will also be evaluated using validated questionnaires.

The study aims to determine whether adding diaphragmatic Kinesio taping to pulmonary rehabilitation provides additional benefits in preserving diaphragm muscle thickness and function in critically ill patients.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Patients admitted to intensive care units are at risk of respiratory muscle weakness and diaphragm dysfunction due to prolonged immobilization, critical illness, and reduced physical activity. These complications may adversely affect respiratory function, exercise tolerance, mobility, and recovery. Pulmonary rehabilitation is an important component of intensive care management and may help reduce the consequences of immobilization and respiratory muscle dysfunction.

Diaphragmatic Kinesio taping is a noninvasive therapeutic approach that may provide additional support to respiratory muscle function when combined with conventional rehabilitation. However, evidence regarding its effects on diaphragm muscle thickness and function in ICU patients remains limited.

This prospective, three-arm, randomized controlled trial will be conducted in the intensive care unit of Istinye University Medical Park Gaziosmanpasa Hospital, Istanbul, Türkiye, between November and December 2026.

A total of 48 eligible patients will be recruited and randomly allocated in a 1:1:1 ratio to one of three groups using computer-generated block randomization. Group allocation will be concealed using sequentially numbered, opaque, sealed envelopes prepared by an independent researcher.

The first group will receive pulmonary rehabilitation combined with diaphragmatic Kinesio taping. The second group will receive pulmonary rehabilitation alone. The third group will receive routine patient education as part of standard hospital care.

The pulmonary rehabilitation program will be administered for three consecutive days and will include positioning, active-assisted range-of-motion exercises, breathing exercises, thoracic expansion exercises, incentive spirometry, and controlled coughing techniques. In the combined intervention group, Kinesio tape will be applied to the anterior and posterior aspects of the trunk along the diaphragmatic region and will remain in place for three days.

Diaphragm muscle thickness at end-inspiration and end-expiration, diaphragm excursion, and diaphragm thickening fraction will be measured by an intensive care physician using ultrasonography. Measurements will be obtained at baseline and after three days. Each ultrasonographic measurement will be repeated three times, and the mean value will be recorded.

Additional assessments will include cough-related quality of life using the Leicester Cough Questionnaire and anxiety and depression symptoms using the Hospital Anxiety and Depression Scale.

The study will evaluate changes in diaphragm morphology and function and compare the effects of the three interventions over the study period.

Tipo di studio

Interventistico

Iscrizione (Stimato)

48

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

19 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Willingness to participate in the study and provision of informed consent.
  2. Age over 18 years.
  3. Requirement for respiratory support as determined by the intensive care physician.
  4. Absence of intellectual disability.
  5. Admission to the intensive care unit due to respiratory distress and suitability for pulmonary rehabilitation as determined by the intensive care physician.

Exclusion Criteria:

  1. Fluctuating level of consciousness.
  2. Glasgow Coma Scale score below 15.
  3. Heart rate below 50 or above 120 beats per minute.
  4. Blood pressure below 90/60 mmHg or above 180/90 mmHg.
  5. New-onset arrhythmia or myocardial ischemia.
  6. Skin lesions or a history of cutaneous hypersensitivity reactions.
  7. Requirement for mechanical ventilation.
  8. Use of sedative medications or neuromuscular blocking agents.
  9. Pregnancy.
  10. Receipt of treatments other than standard intensive care management.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Pulmonary Rehabilitation + Diaphragmatic Kinesio Taping

Participants allocated to this group will receive a structured pulmonary rehabilitation program combined with diaphragmatic Kinesio taping. Pulmonary rehabilitation will be administered for three consecutive days, and Kinesio tape will be applied to the anterior and posterior aspects of the trunk along the diaphragmatic region and will remain in place for three days.

Participants will receive a structured pulmonary rehabilitation program three times daily for three consecutive days. Each session will last approximately 30-45 minutes and will include in-bed positioning, active-assisted range-of-motion exercises, pursed-lip breathing, chest breathing, diaphragmatic breathing, thoracic expansion exercises, maximal inspiratory breath-holding, breathing control, incentive spirometry, and controlled coughing and huffing techniques. Exercises will be performed for 10 repetitions. Heart rate, respiratory rate, blood pressure, and oxygen saturation will be monitored throughout the sessions. The intervention will be discontinued if clinical instability or predefined safety concerns occur.

Diaphragmatic Kinesio taping will be performed using elastic therapeutic tape (Dr. Flexi) and a ligament correction technique. The tape will be applied to the anterior and posterior aspects of the trunk along the costal margins. Anteriorly, the central portion of the tape will be anchored approximately 2.5 cm below the xiphoid process, while posteriorly, the central portion will be anchored at the T12 vertebral level. The tape will be applied with tension along the costal arches, while the ends will remain tension-free. Participants will be instructed to perform deep inspiration during application. The tape will remain in place for three consecutive days. Skin sensitivity will be assessed before application.

Participants allocated to the control group will receive routine patient education as part of standard hospital care. Education will include information about their medical condition, smoking cessation when applicable, preventive health measures, adequate nutrition, avoidance of physical inactivity, vaccination, and the importance of respiratory exercises. Participants' understanding of the educational content will be evaluated through verbal questions.

Comparatore attivo: Pulmonary Rehabilitation

Participants allocated to this group will receive the same structured pulmonary rehabilitation program as the experimental group for three consecutive days. No diaphragmatic Kinesio taping will be applied.

Participants will receive a structured pulmonary rehabilitation program three times daily for three consecutive days. Each session will last approximately 30-45 minutes and will include in-bed positioning, active-assisted range-of-motion exercises, pursed-lip breathing, chest breathing, diaphragmatic breathing, thoracic expansion exercises, maximal inspiratory breath-holding, breathing control, incentive spirometry, and controlled coughing and huffing techniques. Exercises will be performed for 10 repetitions. Heart rate, respiratory rate, blood pressure, and oxygen saturation will be monitored throughout the sessions. The intervention will be discontinued if clinical instability or predefined safety concerns occur.

Participants allocated to the control group will receive routine patient education as part of standard hospital care. Education will include information about their medical condition, smoking cessation when applicable, preventive health measures, adequate nutrition, avoidance of physical inactivity, vaccination, and the importance of respiratory exercises. Participants' understanding of the educational content will be evaluated through verbal questions.

Comparatore attivo: Routine Patient Education

Participants allocated to the control group will receive routine patient education as part of standard hospital care. Education will include information about their medical condition, smoking cessation when applicable, preventive health measures, adequate nutrition, avoidance of physical inactivity, vaccination, and the importance of respiratory exercises. Participants' understanding of the educational content will be evaluated through verbal questions.

Participants allocated to the control group will receive routine patient education as part of standard hospital care. Education will include information about their medical condition, smoking cessation when applicable, preventive health measures, adequate nutrition, avoidance of physical inactivity, vaccination, and the importance of respiratory exercises. Participants' understanding of the educational content will be evaluated through verbal questions.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Diaphragm Muscle Thickness During Inspiration
Lasso di tempo: Baseline and Day 3

End-inspiratory diaphragm muscle thickness will be measured in millimeters using ultrasonography with a high-frequency linear transducer (4-12 MHz). Measurements will be performed with participants in the supine position. Three consecutive measurements will be obtained at each assessment, and the mean value will be calculated. The change in diaphragm muscle thickness from baseline to Day 3 will be evaluated.

Baseline and Day 3
Change in Diaphragm Muscle Thickness During Expiration
Lasso di tempo: Baseline and Day 3

End-expiratory diaphragm muscle thickness will be measured in millimeters using ultrasonography. Three consecutive measurements will be obtained at each assessment, and the mean value will be calculated. Changes in end-expiratory diaphragm muscle thickness between baseline and Day 3 will be evaluated.

Baseline and Day 3

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in Diaphragm Thickening Fraction
Lasso di tempo: Baseline and Day 3

Diaphragm thickening fraction will be calculated using the following formula: [(end-inspiratory diaphragm thickness - end-expiratory diaphragm thickness) / end-expiratory diaphragm thickness] × 100. The results will be expressed as percentages. Changes from baseline to Day 3 will be compared between groups.

Baseline and Day 3
Change in Diaphragm Excursion
Lasso di tempo: Baseline and Day 3

Diaphragm excursion will be assessed using M-mode ultrasonography with a low-frequency curvilinear transducer (2-5 MHz) positioned below the right costal margin. Diaphragmatic movement during respiration will be recorded, and changes between baseline and Day 3 will be evaluated.

Baseline and Day 3
Change in Cough-Related Quality of Life
Lasso di tempo: Baseline and Day 3

Cough-related quality of life will be evaluated using the Leicester Cough Questionnaire (LCQ), which consists of 19 items covering physical, psychological, and social domains. Total scores range from 3 to 21, with higher scores indicating better cough-related quality of life. Changes in total scores from baseline to Day 3 will be evaluated.

Baseline and Day 3
Change in Anxiety Symptoms
Lasso di tempo: Baseline and Day 3

Anxiety symptoms will be assessed using the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). The subscale consists of seven items, with total scores ranging from 0 to 21. Higher scores indicate greater anxiety symptom severity. Changes from baseline to Day 3 will be evaluated.

Baseline and Day 3
Change in Depression Symptoms
Lasso di tempo: Baseline and Day 3

Depression symptoms will be assessed using the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D). The subscale consists of seven items, with total scores ranging from 0 to 21. Higher scores indicate greater depression symptom severity. Changes from baseline to Day 3 will be evaluated.

Baseline and Day 3

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

15 novembre 2026

Completamento primario (Stimato)

15 dicembre 2026

Completamento dello studio (Stimato)

31 dicembre 2026

Date di iscrizione allo studio

Primo inviato

5 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

5 novembre 2026

Primo Inserito (Effettivo)

10 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • BezmialemVU-MTSH

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .